<!DOCTYPE html><!--  This site was created in Webflow. https://www.webflow.com  --><!--  Last Published: Mon May 13 2024 14:36:14 GMT+0000 (Coordinated Universal Time)  -->
<html data-wf-page="65f1ab1547d6f7736ad087e3" data-wf-site="657b2233d6a286f5c9f3844c">
<head>
  <meta charset="utf-8">
  <title>Safety</title>
  <meta content="Safety" property="og:title">
  <meta content="Safety" property="twitter:title">
  <meta content="width=device-width, initial-scale=1" name="viewport">
  <meta content="Webflow" name="generator">
  <link href="css/normalize.css" rel="stylesheet" type="text/css">
  <link href="css/webflow.css" rel="stylesheet" type="text/css">
  <link href="css/yarapage.webflow.css" rel="stylesheet" type="text/css">
  <link href="https://fonts.googleapis.com" rel="preconnect">
  <link href="https://fonts.gstatic.com" rel="preconnect" crossorigin="anonymous">
  <script src="https://ajax.googleapis.com/ajax/libs/webfont/1.6.26/webfont.js" type="text/javascript"></script>
  <script type="text/javascript">WebFont.load({  google: {    families: ["Montserrat:100,100italic,200,200italic,300,300italic,400,400italic,500,500italic,600,600italic,700,700italic,800,800italic,900,900italic","Open Sans:300,300italic,400,400italic,600,600italic,700,700italic,800,800italic","Inter:100,200,300,regular,500,600,700,800,900","Lora:regular,500,600,700,italic,500italic,600italic,700italic","DM Sans:100,200,300,regular,500,600,700,800,900,100italic,200italic,300italic,italic,500italic,600italic,700italic,800italic,900italic","Epilogue:100,200,300,regular,500,600,700,800,900,100italic,200italic,300italic,italic,500italic,600italic,700italic,800italic,900italic","Sora:100,200,300,regular,500,600,700,800","Manrope:200,300,regular,500,600,700,800"]  }});</script>
  <script type="text/javascript">!function(o,c){var n=c.documentElement,t=" w-mod-";n.className+=t+"js",("ontouchstart"in o||o.DocumentTouch&&c instanceof DocumentTouch)&&(n.className+=t+"touch")}(window,document);</script>
  <link href="images/favicon.png" rel="shortcut icon" type="image/x-icon">
  <link href="images/webclip.png" rel="apple-touch-icon">
</head>
<body>
  <section>
    <div class="div-block-981">
      <div class="div-block-983">
        <a href="old-home.html" class="w-inline-block"><img src="images/yara-placeholder.svg" loading="lazy" alt="" class="image-38"></a>
      </div>
      <div class="text-block-165 b">Important Safety Info for GLP-1s</div>
      <div class="text-block-253">See Important Safety Information, including Boxed Warning, about:</div>
      <div class="div-block-1157">
        <div class="text-block-254">
          <a href="#wegovy-safety" class="link-27">Wegovy</a>
        </div>
        <div class="text-block-254">
          <a href="#zepbound-safety" class="link-27">Zepbound</a>
        </div>
        <div class="text-block-254">
          <a href="#ozempic-safety" class="link-27">Ozempic</a>
        </div>
        <div class="text-block-254">
          <a href="#compound-sema" class="link-27">Compound Semaglutide</a>
        </div>
        <div class="text-block-254">
          <a href="#compound-tirzep" class="link-27">Compound Tirzepatide</a>
        </div>
      </div>
    </div>
  </section>
  <section>
    <div class="div-block-984 safety">
      <div>
        <p id="wegovy-safety" class="paragraph-38 b safety">Important Safety Information for Wegovy (semaglutide) injection<br></p>
        <div class="text-block-255">Warning:<strong> </strong>Risk of Thyroid C-Cell Tumors</div>
      </div>
      <p class="paragraph-38">‍<span class="text-span-14"><strong>•</strong></span>In studies with mice and rats, semaglutide (the active ingredient in Wegovy and Ozempic) caused thyroid tumors, including thyroid cancer. It is not known if Wegovy will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.<br><br><span class="text-span-14"><strong>•</strong></span>Do not use Wegovy if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).<br><br><br><span class="text-span-14"><strong>What is the FDA-approved use of Wegovy?</strong></span>  <br>‍<br>Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of:<br>‍<br><span class="text-span-14">•</span><strong>30 kg/m2 or greater (obesity)<br><br></strong><span class="text-span-14"><strong>•</strong></span><strong> 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)</strong><br><br><br><span class="text-span-14"><strong>Limitations of Use:</strong></span><br><br>Wegovy should not be used in combination with other semaglutide-containing products or any other GLP-1 receptor agonist.<br><br>The safety and efficacy of coadministration with other products for weight loss have not been established.<br><br>Wegovy has not been studied in patients with a history of pancreatitis.<br><br><br><span class="text-span-14"><strong>Who should not use Wegovy?</strong></span><br><br><span class="text-span-14"><strong>Do not use Wegovy if:<br>‍<br>•</strong></span>You or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).<br><br><span class="text-span-14"><strong>•</strong></span>You have a known allergic reaction to semaglutide (the active ingredient in Wegovy or Ozempic).<br><br><br><span class="text-span-14"><strong>How should Wegovy be administered?</strong></span><br>‍<br>You can take Wegovy with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Your Yara-affiliated provider will guide you on a treatment regimen that may include an increase in dose every four weeks.<br><br>You should not change your dosing regimen or stop taking Wegovy as prescribed without discussing with your provider first.<br><br><br><span class="text-span-14"><strong>What should I tell my Yara-affiliated provider before using Wegovy?</strong></span><br><br>Wegovy has certain drug interactions. It&#x27;s important to tell your Yara-affiliated provider all of the medications you are currently taking, including<br><br><strong>Some medications to watch out for include:<br><br></strong><span class="text-span-14"><strong>•</strong></span>Medications used to treat type 1 or type 2 diabetes, including insulin or sulfonylureas (such as Amaryl or Glucotrol XL)<br><span class="text-span-14"><strong>•</strong></span>Wegovy causes a delay in gastric emptying, so it has the potential to impact the absorption of medications that are taken by mouth at the same time. Your provider can guide you on how to schedule your medications.<span class="text-span-14"><strong><br>•</strong></span>Other GLP-1 medications, including Ozempic, Saxenda, Victoza, Byetta, or Bydureon<br><span class="text-span-14"><strong>•</strong></span>If you&#x27;re using other products for weight loss, including dietary supplements<br>‍<span class="text-span-14"><strong>•</strong></span>If you&#x27;re taking any other medications, including prescription and over-the-counter medications, vitamins, and herbal supplements.<br><br><br><span class="text-span-14"><strong>It&#x27;s important to share your entire medical history with your provider. In particular, tell your provider if you have a past history of:</strong></span><br><br><span class="text-span-14"><strong>•</strong></span><strong>Type 1 or type 2 diabetes</strong> <br><span class="text-span-14"><strong>•</strong></span><strong>Thyroid cancer</strong> <br><span class="text-span-14"><strong>•</strong></span><strong>Kidney disease<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Pancreatitis</strong><br><span class="text-span-14"><strong>•</strong></span><strong>Depression<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Diabetic retinopathy</strong><br><span class="text-span-14"><strong>•</strong></span><strong>Suicidal thoughts or behavior</strong> <br><br><br><span class="text-span-14"><strong>Tell your provider if you are pregnant, planning to become pregnant, or breastfeeding.<br>‍<br>•</strong></span><strong>If you are pregnant: </strong>Wegovy should not be used during pregnancy. Based on animal studies, there may be potential risks to an unborn baby from exposure to Wegovy during pregnancy. There is no benefit to weight loss during pregnancy and it may cause harm to the unborn baby.<br>‍<span class="text-span-14"><strong>•</strong></span><strong>If you are a female or male of reproductive potential: </strong>Discontinue Wegovy at least 2 months before a planned pregnancy since the drug can stay in the bloodstream for a long time.<br>‍<br><span class="text-span-14"><strong>•</strong></span><strong>If you are breastfeeding: </strong>Wegovy was found in the milk of lactating rats. Tell your Yara-affiliated provider if you are breastfeeding before you start Wegovy.<br>‍<br><strong>Pregnancy registry: </strong>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to semaglutide (the active ingredient in Wegovy and Ozempic) during pregnancy. Pregnant women exposed to semaglutide and healthcare providers are encouraged to contact Novo Nordisk at 1-800-727-6500.<br><br>Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm, including, in some cases, death.<br><br><br><span class="text-span-14"><strong>What are the most serious side effects that I or a caregiver should monitor for when taking Wegovy?</strong></span><br><br>If you are experiencing a medical emergency, call 911 or seek immediate medical attention.<br><br>These serious side effects can occur with Wegovy. You or a caregiver should carefully monitor for these side effects, especially in the beginning of treatment and with dose changes.<br><br>‍<span class="text-span-14"><strong>•</strong></span><strong>Thyroid C-Cell Tumors: </strong>In mice and rats, semaglutide (the active ingredient in Wegovy and Ozempic) caused an increase in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether Wegovy causes thyroid C-cell tumors in humans. There were cases of MTC reported in patients who took liraglutide (the active ingredient in Victoza and Saxenda) after the drug was put on the market. Wegovy is contraindicated in patients with a family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer<br>‍<br><span class="text-span-14"><strong>•</strong></span><strong>Inflammation of Pancreas (Acute Pancreatitis): </strong>Monitor for signs of acute pancreatitis, including severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting.<br>‍<span class="text-span-14"><strong><br>•</strong></span><strong>Acute Gallbladder Disease: </strong>Wegovy may cause gallbladder problems, including gallstones. Some gallbladder problems require surgery. Tell your provider right away if you have pain in your upper stomach, yellowing of skin or eyes (jaundice), fever, or clay-colored stools.<strong><br>‍<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Low Blood Sugar (hypoglycemia): </strong>Wegovy lowers blood glucose. It can cause too low blood sugar in patients with type 2 diabetes who also take another glucose control medication. Monitor your blood sugar and watch out for signs of too low blood sugar such as dizziness, blurred vision, mood changes, sweating, or fast heartbeat.<br>‍<br><span class="text-span-14"><strong>•</strong></span><strong>Acute Kidney Injury: </strong>In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems to get worse. It is important for you to drink plenty of water to help reduce your chance of dehydration.<br>‍<br>‍<span class="text-span-14"><strong>•</strong></span><strong>Serious Allergic Reactions: </strong>Stop using Wegovy right away if you experience symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, or fainting or feeling dizzy.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: </strong>If you have type 2 diabetes, tell your provider right away if you experience changes in vision.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Increase in Heart Rate: </strong>Tell your provider right away if you have a racing heartbeat while at rest.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Suicidal Behavior and Ideation: </strong>You should pay attention to any mental health changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you.<br><br><strong>Never Share a Pen:</strong> Pen-sharing poses a risk of infection.<br>‍<br><br><span class="text-span-14"><strong>What are the most common side effects of Wegovy?</strong></span><br><br><span class="text-span-14"><strong>•</strong></span><strong>Nausea<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Diarrhea<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Vomiting<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Constipation<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Abdominal pain<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Headache<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Fatigue<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Dyspepsia<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Dizziness<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Abdominal distension<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Eructation<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Hypoglycemia in patients with type 2 diabetes<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Flatulence<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Gastrontenritis<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Gastroesophageal reflux disease</strong><br><br><span class="text-span-14"><strong><br>You are encouraged to report negative side effects of prescription products:</strong></span><br><span class="text-span-14"><strong>•</strong></span><strong>Contact Novo Nordisk Inc. at 1-833-934-6891<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Contact FDA MedWatch at 1-800-FDA-1088 or visit www.fda.gov/medwatch</strong><br></p>
    </div>
    <div class="div-block-984 safety">
      <div>
        <p id="wegovy-safety" class="paragraph-38 b safety">Important Safety Information for <span id="zepbound-safety">Zepbound</span> (tirzepatide) injection<br></p>
        <div class="text-block-255">Warning:<strong> </strong>Risk of Thyroid C-Cell Tumors</div>
      </div>
      <p class="paragraph-38">‍<span class="text-span-14"><strong>•</strong></span>In rats, Zepbound caused thyroid tumors, including thyroid cancer. It is not known if Zepbound will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.<br>‍<span class="text-span-14"><strong>•</strong></span>Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).<br>‍<br><br><span class="text-span-14"><strong>What is the FDA-approved use of Zepbound?</strong></span>  <br>‍<br>Zepbound is used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:<br>‍<br><span class="text-span-14">•</span>30 kg/m^2 or greater (obesity)<br>‍<span class="text-span-14"><strong>•</strong></span>27 kg/m^2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease).<br><br><br><span class="text-span-14"><strong>Limitations of Use:</strong></span><br><br><span class="text-span-14">•</span>Zepbound should not be used in combination with other tirzepatide-containing products or any other GLP-1 receptor agonist.<br>‍<br><span class="text-span-14">•</span>The safety and efficacy of coadministration with other products for weight loss have not been established.<br><br><span class="text-span-14">•</span> Zepbound has not been studied in patients with a history of pancreatitis.<br><br><br><span class="text-span-14"><strong>Who should not use Zepbound?</strong></span><br><br><span class="text-span-14"><strong>Do not use Zepbound if:<br>‍<br>•</strong></span>You or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).<br><br><span class="text-span-14"><strong>•</strong></span>You have a known allergic reaction to Zepbound<br><br><br><span class="text-span-14"><strong>How should Zepbound be administered?</strong></span><br>‍<br>You can take Zepbound with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Your Yara-affiliated provider will guide you on a treatment regimen that may include an increase in dose every four weeks.You should not change your dosing regimen or stop taking Zepbound as prescribed without discussing with your provider first.<br><br><br><span class="text-span-14"><strong>What should I tell my Yara-affiliated provider before using Zepbound?</strong></span><br><br>Zepbound has certain drug interactions. It&#x27;s important to tell your Yara-affiliated provider all of the medications you are currently taking, including prescription, over-the-counter medications, vitamins, and herbal and dietary supplements.<br><br><strong>Some medications to watch out for include:<br><br></strong><span class="text-span-14"><strong>•</strong></span><strong>Medications for diabetes: </strong>Medications used to treat type 1 or type 2 diabetes, including insulin or sulfonylureas (such as Amaryl or Glucotrol XL)<br><span class="text-span-14"><strong>•</strong></span><strong>Other oral medications:</strong> Zepbound causes a delay in gastric emptying, so it has the potential to impact the absorption of medications that are taken by mouth at the same time. Your provider can guide you on how to schedule your medications.<span class="text-span-14"><strong><br>•</strong></span><strong>Other GLP-1 medications:</strong> Including Mounjaro, Wegovy, Ozempic, Saxenda, Victoza, Byetta, or Bydureon. These medications should not be taken with Zepbound.<br><span class="text-span-14"><strong>•</strong></span><strong>Hormonal birth control: </strong>If you are using an oral hormonal contraceptive (birth control), Zepbound may decrease its efficacy, especially after the first dose. Switch to a non-oral contraceptive method or use a barrier method ofcontraception for 4 weeks after starting Zepbound and for 4 weeks after each dose escalation, until you reach a maintenance dose.<br>‍<span class="text-span-14"><strong>•</strong></span><strong>Other products for weight loss: </strong>Including dietary supplements<br><br><span class="text-span-14"><strong>It&#x27;s important to share your entire medical history with your provider. In particular, tell your provider if you have a past history of:</strong></span><br><br><span class="text-span-14"><strong>•</strong></span><strong>Type 1 or type 2 diabetes</strong> <br><span class="text-span-14"><strong>•</strong></span><strong>Thyroid cancer</strong> <br><span class="text-span-14"><strong>•</strong></span><strong>Gasrointestinal disease</strong> <br><span class="text-span-14"><strong>•</strong></span><strong>Kidney disease<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Pancreatitis</strong><br><span class="text-span-14"><strong>•</strong></span><strong>Depression<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Diabetic retinopathy</strong><br><span class="text-span-14"><strong>•</strong></span><strong>Suicidal thoughts or behavior</strong> <br><br><br><span class="text-span-14"><strong>Tell your provider if you are pregnant, planning to become pregnant, or breastfeeding.<br>‍<br>•</strong></span><strong>If you are pregnant: </strong>Zepbound should not be used during pregnancy. Based on animal studies, there may be potential risks to an unborn baby from exposure to Zepbound during pregnancy. There is no benefit to weight loss during pregnancy and it may cause harm to the unborn baby.<br>‍<span class="text-span-14"><strong>•</strong></span><strong>If you are a female reproductive potential: </strong>Zepbound may reduce the efficacy of oral hormonal contraceptives. Switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after starting medication and for 4 weeks after each dose escalation until you reach a maintenance dose.<br>‍<br><span class="text-span-14"><strong>•</strong></span><strong>If you are breastfeeding: </strong>It is not known if Zepbound passes into breast milk. Talk to your provider first about the benefits and risks of using Zepbound while breastfeeding.<br>‍<br><strong>Pregnancy registry: </strong>There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Zepbound during pregnancy. Pregnant patients exposed to Zepbound and healthcare providers are encouraged to contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).<br><br>Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm, including, in some cases, death.<br><br><br><span class="text-span-14"><strong>What are the most serious side effects that I or a caregiver should monitor for when taking Zepbound?</strong></span><br><br>If you are experiencing a medical emergency, call 911 or seek immediate medical attention.<br><br>These serious side effects are rare, but can occur with Zepbound. You or a caregiver should carefully monitor for these side effects, especially in the beginning of treatment and with dose changes.<br><br>‍<span class="text-span-14"><strong>•</strong></span><strong>Thyroid C-Cell Tumors: </strong>In rats, Zepbound caused a dose-dependent and treatment-duration-dependent increase in thyroid C-cell tumors. It is unknown whether Zepbound causes thyroid C-cell tumors in humans. Zepbound is contraindicated in patients with a family history of medullary thyroid cancer (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.These may be symptoms of thyroid cancer.<br>‍<br><span class="text-span-14"><strong>•</strong></span><strong>Severe Gastrointestinal Disease: </strong>Zepbound is associated with gastrointestinal side effects, such as nausea, diarrhea, vomiting, constipation, and stomach pain, and can sometimes be severe. It hasn&#x27;t been studied in patients with severe gastrointestinal disease and isn&#x27;t recommended in these patients. The majority of nausea, vomiting, and/or diarrhea events occurred during a dose increase and decreased over time.<br>‍<span class="text-span-14"><strong><br>•</strong></span><strong>Acute Kidney Injury: </strong>Gastrointestinal side effects of Zepbound like diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems if dehydration is severe. It is important for you to drink plenty of water to help reduce your chance of dehydration.<br>‍<span class="text-span-14"><strong>•</strong></span><strong>Acute Gallbladder Disease: </strong>Zepbound, other GLP-1 receptor agonists, and weight loss are associated with an increased chance of acute gallbladder disease. Tell your provider right away if you have pain in your upper stomach, yellowing of skin or eyes(jaundice), fever, or clay - colored stools.<br>‍<br><span class="text-span-14"><strong>•</strong></span><strong>Inflammation of Pancreas (Acute Pancreatitis): </strong>Monitor for signs of acute pancreatitis, including severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting.<br>‍<br>‍<span class="text-span-14"><strong>•</strong></span><strong>Serious Allergic Reactions: </strong>Stop using Wegovy right away if you experience symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, or fainting or feeling dizzy.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Allergic Reactions: </strong>Stop using Zepbound right away if you experience symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, or fainting or feeling dizzy.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Low Blood Sugar (Hypoglycemia): </strong>Zepbound lowers blood glucose. It can cause too low blood sugar in patients with type 2 diabetes who also take another glucose control medication. Monitor your blood sugar and watch out for signs of too low blood sugar such as dizziness, blurred vision, mood changes, sweating, or fast heartbeat.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy: </strong>Rapid improvement of glucose control has been associated with temporary worsening of diabetic retinopathy. Tell your provider right away if you experience changes in vision.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Suicidal Behavior and Ideation: </strong>You should pay attention to any mental health changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Never Share a Pen:</strong> Pen-sharing poses a risk of infection.<br>‍<br><br><span class="text-span-14"><strong>What are the most common side effects of Zepbound?</strong></span><br><br><span class="text-span-14"><strong>•</strong></span><strong>Nausea<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Diarrhea<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Vomiting<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Constipation<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Indigestion<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Injection site reactions<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Fatigue<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Allergic reactions<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Belching<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Hair loss</strong><span class="text-span-14"><br><strong>•</strong></span><strong>Gastroesophageal reflux disease</strong><br><br><span class="text-span-14"><strong><br>You are encouraged to report negative side effects of prescription products to the FDA:</strong></span><br><span class="text-span-14"><strong>•</strong></span><strong>Visit www.fda.gov/medwatch or call 1-800-FDA-1088.<br></strong><br></p>
    </div>
    <div class="div-block-984 safety">
      <div>
        <p id="wegovy-safety" class="paragraph-38 b safety">Important Safety Information for <span id="ozempic-safety">Ozempic</span> (semaglutide) injection<br></p>
        <div class="text-block-255">Warning:<strong> </strong>Risk of Thyroid C-Cell Tumors</div>
      </div>
      <p class="paragraph-38">‍<span class="text-span-14"><strong>•</strong></span>In studies with mice and rats, semaglutide (the active ingredient in Ozempic and Wegovy) caused thyroid tumors, including thyroid cancer. It is not known if Ozempic will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.These may be symptoms of thyroid cancer.<br><br><span class="text-span-14"><strong>•</strong></span>Do not use Ozempic if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).<br><br><br><span class="text-span-14"><strong>What is the FDA-approved use of Ozempic?<br>‍</strong></span>‍<br>Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist that is used:<br>‍<br><span class="text-span-14">•</span><strong>with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.<br><br></strong><span class="text-span-14"><strong>•</strong></span><strong>to reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus and established cardiovascular disease.</strong><br><br><br><span class="text-span-14"><strong>Limitations of Use:</strong></span><br><br>Ozempic is not for treatment of type 1 diabetes mellitus.<br><br>Ozempic has not been studied in patients with a history of pancreatitis.<br><br>Your Yara-affiliated provider may recommend the use of Ozempic as treatment for chronic weight management (obesity or overweight).<br><br><br><span class="text-span-14"><strong>Who should not use Ozempic?</strong></span><br><br><span class="text-span-14"><strong>Do not use Ozempic if:<br>‍<br>•</strong></span>You or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).<br><br><span class="text-span-14"><strong>•</strong></span>You have a known allergic reaction to semaglutide (the active ingredient in Wegovy or Ozempic).<br><br><br><span class="text-span-14"><strong>How should Ozempic be administered?</strong></span><br>‍<br>You can take Ozempic with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Your Yara-affiliated provider will guide you on a treatment regimen that may include an increase in dose every four weeks.<br><br>You should not change your dosing regimen or stop taking Ozempic as prescribed without discussing with your provider first.<br><br><br><span class="text-span-14"><strong>What should I tell my Yara-affiliated provider before using Ozempic?</strong></span><br><br>Ozempic has certain drug interactions. It&#x27;s important to tell your Yara-affiliated provider all of the medications you are currently taking, including prescription, over-the-counter medications, vitamins, and herbal and dietary supplements.<br><br><strong>Some medications to watch out for include:<br><br></strong><span class="text-span-14"><strong>•</strong></span>Medications used to treat type 1 or type 2 diabetes, including insulin or sulfonylureas (such as Amaryl or Glucotrol XL)<br><span class="text-span-14"><strong>•</strong></span>Ozempic causes a delay in gastric emptying so it has the potential to impact the absorption of medications that are taken by mouth at the same time.Your provider can guide you on how to schedule your medications.<span class="text-span-14"><strong><br>•</strong></span>Other GLP-1 medications, including Wegovy, Saxenda, Victoza, Byetta, or Bydureon<br>‍<span class="text-span-14"><strong>•</strong></span>If you&#x27;re using other products for weight loss, including dietary supplements<br><br><span class="text-span-14"><strong>It&#x27;s important to share your entire medical history with your provider. In particular, tell your provider if you have a past history of:</strong></span><br><br><span class="text-span-14"><strong>•</strong></span><strong>Type 1 or type 2 diabetes</strong> <br><span class="text-span-14"><strong>•</strong></span><strong>Thyroid cancer</strong> <br><span class="text-span-14"><strong>•</strong></span><strong>Kidney disease<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Pancreatitis</strong><br><span class="text-span-14"><strong>•</strong></span><strong>Depression<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Diabetic retinopathy</strong><br><span class="text-span-14"><strong>•</strong></span><strong>Suicidal thoughts or behavior</strong> <br><br><br><span class="text-span-14"><strong>Tell your provider if you are pregnant, planning to become pregnant, or breastfeeding.<br>‍<br>•</strong></span><strong>If you are pregnant: </strong>Ozempic should not be used during pregnancy. Based on animal studies, there may be potential risks to an unborn baby from exposure to Ozempic during pregnancy. There is no benefit to weight loss during pregnancy and it may cause harm to the unborn baby.<br>‍<span class="text-span-14"><strong>•</strong></span><strong>If you are a female or male of reproductive potential: </strong>Discontinue Ozempic at least 2 months before a planned pregnancy since the drug can stay in the bloodstream for a long time.<br><span class="text-span-14"><strong>•</strong></span><strong>If you are breastfeeding: </strong>Ozempic was found in the milk of lactating rats. Tell your Yara-affiliated provider if you are breastfeeding before you start Ozempic.<br>‍<br><strong>Pregnancy registry: </strong>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to semaglutide (the active ingredient in Ozempic and Ozempic) during pregnancy. Pregnant women exposed to semaglutide and healthcare providers are encouraged to contact Novo Nordisk at 1-800 - 727 - 6500.<br><br>Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm, including, in some cases, death.<br><br><span class="text-span-14"><strong>What are the most serious side effects that I or a caregiver should monitor for when taking Ozempic?</strong></span><br><br>If you are experiencing a medical emergency, call 911 or seek immediate medical attention.<br><br><strong>These serious side effects can occur with Ozempic. You or a caregiver should carefully monitor for these side effects, especially in the beginning of treatment and with dose changes.</strong><br><br><span class="text-span-14"><strong>•</strong></span><strong>Thyroid C-Cell Tumors: </strong>In mice and rats, semaglutide (the active ingredient in Ozempic and Ozempic) caused an increase in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether Ozempic causes thyroid C-cell tumors in humans. There were cases of MTC reported in patients who took liraglutide (the active ingredient in Victoza and Saxenda) after the drug was put on the market. Ozempic is contraindicated in patients with a family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).<br>‍<br><span class="text-span-14"><strong>•</strong></span>Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.<br>‍<span class="text-span-14"><strong><br>•</strong></span><strong>Inflammation of Pancreas (Acute Pancreatitis): </strong>Monitor for signs of acute pancreatitis, including severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting.<strong><br>‍<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: </strong>If you have type 2 diabetes, tell your provider right away if you experience changes in vision.<br>‍<br><span class="text-span-14"><strong>•</strong></span><strong>Never Share a Pen:</strong> Pen-sharing poses a risk of infection.<br>‍<br>‍<span class="text-span-14"><strong>•</strong></span><strong>Low Blood Sugar (hypoglycemia): </strong>Ozempic lowers blood glucose. It can cause too low blood sugar in patients with type 2 diabetes who also take another glucose control medication. Monitor your blood sugar and watch out for signs of too low blood sugar such as dizziness, blurred vision, mood changes, sweating, or fast heartbeat.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Acute Kidney Injury: </strong>In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems to get worse. It is important for you to drink plenty of water to help reduce your chance of dehydration.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Serious Allergic Reactions: </strong>Stop using Ozempic right away if you experience symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, or fainting or feeling dizzy.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Acute Gallbladder Disease: </strong>Ozempic may cause gallbladder problems, including gallstones. Some gallbladder problems require surgery. Tell your provider right away if you have pain in your upper stomach, yellowing of skin or eyes (jaundice), fever, or clay-colored stools.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Increase in Heart Rate: </strong>Tell your provider right away if you have a racing heartbeat while at rest.<br><br>‍<span class="text-span-14"><strong>•</strong></span><strong>Suicidal Behavior and Ideation: </strong>You should pay attention to any mental health changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you.<br>‍<br><br><span class="text-span-14"><strong>What are the most common side effects of Ozempic?</strong></span><br><br><span class="text-span-14"><strong>•</strong></span><strong>Nausea<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Diarrhea<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Vomiting<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Constipation<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Stomach pain</strong><br><br><span class="text-span-14"><strong><br>You are encouraged to report negative side effects of prescription products:</strong></span><br><span class="text-span-14"><strong>•</strong></span><strong>Contact Novo Nordisk Inc. at 1-833-934-6891<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Contact FDA MedWatch at 1-800-FDA-1088 or visit www.fda.gov/medwatch</strong><br></p>
    </div>
    <div class="div-block-984 safety">
      <div>
        <p id="wegovy-safety" class="paragraph-38 b safety">Important Safety Information for <span id="compound-sema">Compound Semaglutide</span> injection<br></p>
        <div class="text-block-255">Warning:<strong> </strong>Risk of Thyroid C-Cell Tumors</div>
      </div>
      <p class="paragraph-38">‍<span class="text-span-14"><strong>•</strong></span>In studies with mice and rats, semaglutide (the active ingredient in Wegovy and Ozempic) caused thyroid tumors, including thyroid cancer. It is not known if Wegovy will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.<br><br><span class="text-span-14"><strong>•</strong></span>Do not use Wegovy if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).<br><br><br><span class="text-span-14"><strong>What is the FDA-approved use of Wegovy?</strong></span>  <br>‍<br>Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of:<br>‍<br><span class="text-span-14">•</span><strong>30 kg/m2 or greater (obesity)<br><br></strong><span class="text-span-14"><strong>•</strong></span><strong> 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)</strong><br><br><br><span class="text-span-14"><strong>Limitations of Use:</strong></span><br><br>Wegovy should not be used in combination with other semaglutide-containing products or any other GLP-1 receptor agonist.<br><br>The safety and efficacy of coadministration with other products for weight loss have not been established.<br><br>Wegovy has not been studied in patients with a history of pancreatitis.<br><br><br><span class="text-span-14"><strong>Who should not use Wegovy?</strong></span><br><br><span class="text-span-14"><strong>Do not use Wegovy if:<br>‍<br>•</strong></span>You or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).<br><br><span class="text-span-14"><strong>•</strong></span>You have a known allergic reaction to semaglutide (the active ingredient in Wegovy or Ozempic).<br><br><br><span class="text-span-14"><strong>How should Wegovy be administered?</strong></span><br>‍<br>You can take Wegovy with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Your Yara-affiliated provider will guide you on a treatment regimen that may include an increase in dose every four weeks.<br><br>You should not change your dosing regimen or stop taking Wegovy as prescribed without discussing with your provider first.<br><br><br><span class="text-span-14"><strong>What should I tell my Yara-affiliated provider before using Wegovy?</strong></span><br><br>Wegovy has certain drug interactions. It&#x27;s important to tell your Yara-affiliated provider all of the medications you are currently taking, including<br><br>Compounded drugs are permitted to be prescribed under federal law but are not FDA-approved and do not undergo safety, effectiveness, or manufacturing review. Your IvimHealth provider may recommend certain doses of Compound Semaglutide based on your medical evaluation.<br><br><strong>Indications and Use:<br>‍<br></strong>Compound Semaglutide is an injectable prescription medicine that may help adults with obesity, or with excess weight (overweight) who also have weight-related medical problems, lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity.<br><br><br><span class="text-span-14"><strong>What is the FDA-approved use of Wegovy?</strong></span>  <br><br>Compound Semaglutide is an injectable prescription medicine that may help adults with obesity, or with excess weight (overweight) who also have weight-related medical problems, lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity.<br>‍<br>Compound Semaglutide is a synthetic, dual-acting glucagon-like peptide-1 (GLP-1) and GIP receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of:<br>‍<br><span class="text-span-14">•</span><strong>30 kg/m2 or greater (obesity)<br><br></strong><span class="text-span-14"><strong>•</strong></span><strong> 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)<br><br></strong>Compound Semaglutide should not be used with other Semaglutide-containing products or any GLP-1 receptor agonist medicines. It is not known if Semaglutide is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products. It is not known if Semaglutide can be used in people who have had pancreatitis. It is not known if Semaglutide is safe and effective for use in children under 18 years of age.<br><br><br><span class="text-span-14"><strong>Important Safety Information for Compound Semaglutide injection<br></strong></span><strong>Warning: Risk of Thyroid C-Cell Tumors</strong><br>‍<br>In studies with mice and rats, semaglutide (the active ingredient in Wegovy and Ozempic) caused thyroid tumors, including thyroid cancer. It is not known if Compound Semaglutide will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.<br><br>Do not use Compound Semaglutide if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).<br><br><br><span class="text-span-14"><strong>What is the FDA-approved use of Compound Semaglutide?</strong></span>  <br>‍<br>Compound Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of:<br>‍<br><span class="text-span-14">•</span><strong>30 kg/m2 or greater (obesity)<br><br></strong><span class="text-span-14"><strong>•</strong></span><strong> 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)<br></strong><br><br><span class="text-span-14"><strong>Limitations of Use:</strong></span><br><br><span class="text-span-14"><strong>•</strong></span>Compound Semaglutide should not be used in combination with other semaglutide-containing products or any other GLP-1 receptor agonist.<br><br><span class="text-span-14"><strong>•</strong></span>The safety and efficacy of coadministration with other products for weight loss have not been established.<br><br><span class="text-span-14"><strong>•</strong></span>Compound Semaglutide has not been studied in patients with a history of pancreatitis<br><br><br><span class="text-span-14"><strong>Who should not use Compound Semaglutide?</strong></span><br><br><span class="text-span-14"><strong>Do not use Compound Semaglutide if:<br>‍<br>•</strong></span>You or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).<br><br><span class="text-span-14"><strong>•</strong></span>You have a known allergic reaction to semaglutide (the active ingredient in Wegovy or Ozempic).<br><br><br><span class="text-span-14"><strong>How should Semaglutide be administered?</strong></span><br>‍<br>You can take Semaglutide with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week onthe same day every week. Your Ivím provider will guide you on a treatment regimen that may include an increase in dose every four weeks.You should not change your dosing regimen or stop taking Semaglutide as prescribed without discussing with your provider first.<br><br><br><span class="text-span-14"><strong>What should I tell my Ivím provider before using Semaglutide?</strong></span><br><br>Semaglutide has certain drug interactions. It&#x27;s important to tell your Ivím provider all of the medications you are currently taking, including prescription, over-the-countermedications, vitamins, and herbal and dietary supplements.<br><br><strong>Some medications to watch out for include:<br>‍</strong>‍<br><span class="text-span-14"><strong>•</strong></span>Medications used to treat type 1 or type 2 diabetes, including insulin or sulfonylureas (such as Amaryl or Glucotrol XL)<br>‍<span class="text-span-14"><strong>•</strong></span>Semaglutide causes a delay in gastric emptying, so it has the potential to impact the absorption of medications that are taken by mouth at the same time. Your provider canguide you on how to schedule your medications.<br>‍<span class="text-span-14"><strong>•</strong></span>Other GLP-1 medications, including Ozempic, Saxenda, Victoza, Byetta, or Bydureon<br>‍<span class="text-span-14"><strong>•</strong></span>If you&#x27;re using other products for weight loss, including dietary supplements<br>‍<span class="text-span-14">‍<br></span><br><span class="text-span-14"><strong>It&#x27;s important to share your entire medical history with your provider. In particular, tell your provider if you have a past history of:</strong></span><br><br><span class="text-span-14"><strong>•</strong></span><strong>Type 1 or type 2 diabetes</strong> <br><span class="text-span-14"><strong>•</strong></span><strong>Thyroid cancer</strong> <br><span class="text-span-14"><strong>•</strong></span><strong>Kidney disease<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Pancreatitis</strong><br><span class="text-span-14"><strong>•</strong></span><strong>Depression<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Diabetic retinopathy</strong><br><span class="text-span-14"><strong>•</strong></span><strong>Suicidal thoughts or behavior</strong> <br><br><br><span class="text-span-14"><strong>Tell your provider if you are pregnant, planning to become pregnant, or breastfeeding.<br>‍<br>•</strong></span><strong>If you are pregnant: </strong>Semaglutide should not be used during pregnancy. Based on animal studies, there may be potential risks to an unborn baby from exposure to Semaglutide during pregnancy. There is no benefit to weight loss during pregnancy and it may cause harm to the unborn baby.<br>‍<span class="text-span-14"><strong>•</strong></span><strong>If you are a female or male of reproductive potential: </strong>Discontinue Semaglutide at least 2 months before a planned pregnancy since the drug can stay in the bloodstream for a long time.<br>‍<br><span class="text-span-14"><strong>•</strong></span><strong>If you are breastfeeding: </strong>Semaglutide was found in the milk of lactating rats. Tell your Ivím provider if you are breastfeeding before you start Semaglutide.<br>‍<br><strong>Pregnancy registry: </strong>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to semaglutide (the active ingredient in Semaglutide and Ozempic) during pregnancy. Pregnant women exposed to semaglutide and healthcare providers are encouraged to contact Novo Nordisk at 1-800-727-6500.<br><br>Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm, including, in some cases, death.<br><br><br><span class="text-span-14"><strong>What are the most serious side effects that I or a caregiver should monitor for when taking Semaglutide?</strong></span><br><br>If you are experiencing a medical emergency, call 911 or seek immediate medical attention.<br><br><strong>These serious side effects can occur with Semaglutide. You or a caregiver should carefully monitor for these side effects, especially in the beginning of treatment and with dose changes.</strong><br><br><span class="text-span-14"><strong>•</strong></span><strong>Thyroid C-Cell Tumors: </strong>In mice and rats, semaglutide (the active ingredient in Semaglutide and Ozempic) caused an increase in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether Semaglutide causes thyroid C-cell tumors in humans. There were cases of MTC reported in patients who took liraglutide (the active ingredient in Victoza and Saxenda) after the drug was put on the market. Semaglutide is contraindicated in patients with a family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.<br>‍<br><span class="text-span-14"><strong>•</strong></span><strong>Inflammation of Pancreas (Acute Pancreatitis): </strong>Monitor for signs of acute pancreatitis, including severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting.<br>‍<span class="text-span-14"><strong><br>•</strong></span><strong>Acute Gallbladder Disease: </strong>Semaglutide may cause gallbladder problems, including gallstones. Some gallbladder problems require surgery. Tell your provider right away if you have pain in your upper stomach, yellowing of skin or eyes (jaundice), fever, or clay-colored stools.<strong><br>‍<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Low Blood Sugar (hypoglycemia): </strong>Semaglutide lowers blood glucose. It can cause too low blood sugar in patients with type 2 diabetes who also take another glucose control medication. Monitor your blood sugar and watch out for signs of too low blood sugar such as dizziness, blurred vision, mood changes, sweating, or fast heartbeat.<br>‍<br><span class="text-span-14"><strong>•</strong></span><strong>Acute Kidney Injury: </strong>In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems to get worse. It is important for you to drink plenty of water to help reduce your chance of dehydration.<br>‍<br>‍<span class="text-span-14"><strong>•</strong></span><strong>Serious Allergic Reactions: </strong>Stop using Semaglutide right away if you experience symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, or fainting or feeling dizzy.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: </strong>If you have type 2 diabetes, tell your provider right away if you experience changes in vision.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Increase in Heart Rate: </strong>Tell your provider right away if you have a racing heartbeat while at rest.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Suicidal Behavior and Ideation: </strong>You should pay attention to any mental health changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you.<br><br><strong>Never Share a Pen:</strong> Pen-sharing poses a risk of infection.<br>‍<br><br><span class="text-span-14"><strong>What are the most common side effects of Semaglutide?</strong></span><br><br><span class="text-span-14"><strong>•</strong></span><strong>Nausea<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Diarrhea<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Vomiting<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Constipation<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Stomach pain<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Indigestion<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Injection site reactions<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Feeling tired<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Allergic reactions<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Belching<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Hair loss<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Gastroesophageal reflux disease (heartburn)</strong><br><br><span class="text-span-14"><strong><br>You are encouraged to report negative side effects of prescription products:</strong></span><br><span class="text-span-14"><strong>•</strong></span><strong>Contact Novo Nordisk Inc. at 1-833-934-6891<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Contact FDA MedWatch at 1-800-FDA-1088 or visit www.fda.gov/medwatch</strong><br><br><span class="text-span-14"><strong>Before using Compound Semaglutide<br>‍<br>•</strong></span>Your healthcare provider should show you how to use Compound Semaglutide before you use it for the first time.<strong><br>‍</strong><span class="text-span-14"><strong>•</strong></span>Tell your healthcare provider if you are taking medicines to treat diabetes including insulin or sulfonylureas which could increase your risk of low blood sugar. Talk to your healthcare provider about low blood sugar levels and how to manage them.<strong><br>‍</strong><span class="text-span-14"><strong>•</strong></span>If you take birth control pills by mouth, talk to your healthcare provider before you use Compound Semaglutide.<br>‍<span class="text-span-14"><strong>•</strong></span>Birth control pills may not work as well while using Compound Semaglutide. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Compound Semaglutide and for 4 weeks after each increase in your dose of Compound Semaglutide.<br><br><br><span class="text-span-14"><strong>Review these questions with your healthcare provider:<br>‍<br>•</strong></span>Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?<strong><br>‍</strong><span class="text-span-14"><strong>•</strong></span>Do you take diabetes medicines, such as insulin or sulfonylureas ?<strong><br>‍</strong><span class="text-span-14"><strong>•</strong></span>Do you have a history of diabetic retinopathy?<br>‍<span class="text-span-14"><strong>•</strong></span>Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?<br><span class="text-span-14"><strong>•</strong></span>Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Compound Semaglutide may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Compound Semaglutide. It is not known if Compound Semaglutide passes into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Compound Semaglutide.<br><br><br><span class="text-span-14"><strong>How to take<br>‍<br>•</strong></span>Read the Instructions for Use that come with Compound Semaglutide.<br>‍<span class="text-span-14"><strong>•</strong></span>Use Compound Semaglutide exactly as your healthcare provider says.<strong><br>‍</strong><span class="text-span-14"><strong>•</strong></span>Compound Semaglutide is injected under the skin(subcutaneously) of your stomach(abdomen), thigh, or upper arm.<br>‍<span class="text-span-14"><strong>•</strong></span>Use Compound Semaglutide 1 time each week, at any time of the day.<br><span class="text-span-14"><strong>•</strong></span>Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection.<strong><br>‍</strong><span class="text-span-14"><strong>•</strong></span>If you take too much Compound Semaglutide, call your healthcare provider, seek medical advice promptly, or contact a Poison Center expert right away at 1-800-222-1222.<br>‍<br><br><span class="text-span-14"><strong>Learn More</strong><br></span><br>This summary provides basic information about Compound Semaglutide but does not include all information known about this medicine.Read the information that comes with your prescription each time your prescription is filled.This information does not take the place of talking with your healthcare provider.Be sure to talk to your healthcare provider about Compound Semaglutide and how to take it.Your healthcare provider is the best person to help you decide if Compound Semaglutide is right for you.<br></p>
    </div>
    <div class="div-block-984">
      <div>
        <p id="wegovy-safety" class="paragraph-38 b safety">Important Safety Information for <span id="compound-tirzep">Compound Tirzepatide</span> injection<br></p>
        <div class="text-block-255">Warning:<strong> </strong>Risk of Thyroid C-Cell Tumors</div>
      </div>
      <p class="paragraph-38">Compounded drugs are permitted to be prescribed under federal law but are not FDA-approved and do not undergo safety, effectiveness, or manufacturing review. Your Ivim Health provider may recommend certain doses of Compound Tirzepatide based on your medical evaluation.<br><br><span class="text-span-14"><strong>Indications and Use:</strong></span><br><br>Compound Tirzepatide is an injectable prescription medicine that may help adults with obesity, or with excess weight (overweight) who also have weight-related medical problems, lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity. Compound Tirzepatide is a synthetic, dual-acting glucagon-like peptide-1 (GLP-1) and GIP receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of:<br><br><span class="text-span-14">•</span>30 kg/m2 or greater (obesity) or<br><span class="text-span-14">•</span>27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).<br><br>Compound Tirzepatide should not be used with other Tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Tirzepatide is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products. It is not known if Tirzepatide can be used in people who have had pancreatitis. It is not known if Tirzepatide is safe and effective for use in children under 18 years of age.<br><br><span class="text-span-14"><strong>Important Safety Information for Zepbound (tirzepatide) injection<br></strong></span><br>‍<span class="text-span-14"><strong>•</strong></span>In rats, Zepbound caused thyroid tumors, including thyroid cancer. It is not known if Zepbound will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.<br>‍<span class="text-span-14"><strong>•</strong></span>Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).<br>‍<br><br><span class="text-span-14"><strong>What is the FDA-approved use of Zepbound?</strong></span>  <br>‍<br>Zepbound is used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:<br>‍<br><span class="text-span-14">•</span>30 kg/m^2 or greater (obesity)<br>‍<span class="text-span-14"><strong>•</strong></span>27 kg/m^2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease).<br><br><br><span class="text-span-14"><strong>Limitations of Use:</strong></span><br><br><span class="text-span-14">•</span>Zepbound should not be used in combination with other tirzepatide-containing products or any other GLP-1 receptor agonist.<br>‍<br><span class="text-span-14">•</span>The safety and efficacy of coadministration with other products for weight loss have not been established.<br><br><span class="text-span-14">•</span> Zepbound has not been studied in patients with a history of pancreatitis.<br><br><br><span class="text-span-14"><strong>Who should not use Zepbound?</strong></span><br><br><span class="text-span-14"><strong>Do not use Zepbound if:<br>‍<br>•</strong></span>You or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).<br><br><span class="text-span-14"><strong>•</strong></span>You have a known allergic reaction to Zepbound<br><br><br><span class="text-span-14"><strong>How should Zepbound be administered?</strong></span><br>‍<br>You can take Zepbound with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Your Yara-affiliated provider will guide you on a treatment regimen that may include an increase in dose every four weeks.<br><br>You should not change your dosing regimen or stop taking Zepbound as prescribed without discussing with your provider first.<br><br><br><span class="text-span-14"><strong>What should I tell my Yara-affiliated provider before using Zepbound?</strong></span><br><br>Zepbound has certain drug interactions. It&#x27;s important to tell your Yara-affiliated provider all of the medications you are currently taking, including prescription, over-the-counter medications, vitamins, and herbal and dietary supplements.<br><br><strong>Some medications to watch out for include:<br><br></strong><span class="text-span-14"><strong>•</strong></span><strong>Medications for diabetes: </strong>Medications used to treat type 1 or type 2 diabetes, including insulin or sulfonylureas (such as Amaryl or Glucotrol XL)<br><span class="text-span-14"><strong>•</strong></span><strong>Other oral medications:</strong> Zepbound causes a delay in gastric emptying, so it has the potential to impact the absorption of medications that are taken by mouth at the same time. Your provider can guide you on how to schedule your medications.<span class="text-span-14"><strong><br>•</strong></span><strong>Other GLP-1 medications:</strong> Including Mounjaro, Wegovy, Ozempic, Saxenda, Victoza, Byetta, or Bydureon. These medications should not be taken with Zepbound.<br><span class="text-span-14"><strong>•</strong></span><strong>Hormonal birth control: </strong>If you are using an oral hormonal contraceptive (birth control), Zepbound may decrease its efficacy, especially after the first dose. Switch to a non-oral contraceptive method or use a barrier method ofcontraception for 4 weeks after starting Zepbound and for 4 weeks after each dose escalation, until you reach a maintenance dose.<br>‍<span class="text-span-14"><strong>•</strong></span><strong>Other products for weight loss: </strong>Including dietary supplements<br><br><span class="text-span-14"><strong>It&#x27;s important to share your entire medical history with your provider. In particular, tell your provider if you have a past history of:</strong></span><br><br><span class="text-span-14"><strong>•</strong></span><strong>Type 1 or type 2 diabetes</strong> <br><span class="text-span-14"><strong>•</strong></span><strong>Thyroid cancer</strong> <br><span class="text-span-14"><strong>•</strong></span><strong>Gasrointestinal disease</strong> <br><span class="text-span-14"><strong>•</strong></span><strong>Kidney disease<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Pancreatitis</strong><br><span class="text-span-14"><strong>•</strong></span><strong>Depression<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Diabetic retinopathy</strong><br><span class="text-span-14"><strong>•</strong></span><strong>Suicidal thoughts or behavior</strong> <br><br><br><span class="text-span-14"><strong>Tell your provider if you are pregnant, planning to become pregnant, or breastfeeding.<br>‍<br>•</strong></span><strong>If you are pregnant: </strong>Zepbound should not be used during pregnancy. Based on animal studies, there may be potential risks to an unborn baby from exposure to Zepbound during pregnancy. There is no benefit to weight loss during pregnancy and it may cause harm to the unborn baby.<br>‍<span class="text-span-14"><strong>•</strong></span><strong>If you are a female reproductive potential: </strong>Zepbound may reduce the efficacy of oral hormonal contraceptives. Switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after starting medication and for 4 weeks after each dose escalation until you reach a maintenance dose.<br>‍<br><span class="text-span-14"><strong>•</strong></span><strong>If you are breastfeeding: </strong>It is not known if Zepbound passes into breast milk. Talk to your provider first about the benefits and risks of using Zepbound while breastfeeding.<br>‍<br><strong>Pregnancy registry: </strong>There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Zepbound during pregnancy. Pregnant patients exposed to Zepbound and healthcare providers are encouraged to contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).<br><br>Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm, including, in some cases, death.<br><br><br><span class="text-span-14"><strong>What are the most serious side effects that I or a caregiver should monitor for when taking Zepbound?</strong></span><br><br>If you are experiencing a medical emergency, call 911 or seek immediate medical attention.<br><br>These serious side effects are rare, but can occur with Zepbound. You or a caregiver should carefully monitor for these side effects, especially in the beginning of treatment and with dose changes.<br><br>‍<span class="text-span-14"><strong>•</strong></span><strong>Thyroid C-Cell Tumors: </strong>In rats, Zepbound caused a dose-dependent and treatment-duration-dependent increase in thyroid C-cell tumors. It is unknown whether Zepbound causes thyroid C-cell tumors in humans. Zepbound is contraindicated in patients with a family history of medullary thyroid cancer (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.These may be symptoms of thyroid cancer.<br>‍<br><span class="text-span-14"><strong>•</strong></span><strong>Severe Gastrointestinal Disease: </strong>Zepbound is associated with gastrointestinal side effects, such as nausea, diarrhea, vomiting, constipation, and stomach pain, and can sometimes be severe. It hasn&#x27;t been studied in patients with severe gastrointestinal disease and isn&#x27;t recommended in these patients. The majority of nausea, vomiting, and/or diarrhea events occurred during a dose increase and decreased over time.<br>‍<span class="text-span-14"><strong><br>•</strong></span><strong>Acute Kidney Injury: </strong>Gastrointestinal side effects of Zepbound like diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems if dehydration is severe. It is important for you to drink plenty of water to help reduce your chance of dehydration.<br>‍<br>‍<span class="text-span-14"><strong>•</strong></span><strong>Acute Gallbladder Disease: </strong>Zepbound, other GLP-1 receptor agonists, and weight loss are associated with an increased chance of acute gallbladder disease. Tell your provider right away if you have pain in your upper stomach, yellowing of skin or eyes(jaundice), fever, or clay - colored stools.<br>‍<br><span class="text-span-14"><strong>•</strong></span><strong>Inflammation of Pancreas (Acute Pancreatitis): </strong>Monitor for signs of acute pancreatitis, including severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting.<br>‍<br>‍<span class="text-span-14"><strong>•</strong></span><strong>Serious Allergic Reactions: </strong>Stop using Wegovy right away if you experience symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, or fainting or feeling dizzy.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Allergic Reactions: </strong>Stop using Zepbound right away if you experience symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, or fainting or feeling dizzy.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Low Blood Sugar (Hypoglycemia): </strong>Zepbound lowers blood glucose. It can cause too low blood sugar in patients with type 2 diabetes who also take another glucose control medication. Monitor your blood sugar and watch out for signs of too low blood sugar such as dizziness, blurred vision, mood changes, sweating, or fast heartbeat.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy: </strong>Rapid improvement of glucose control has been associated with temporary worsening of diabetic retinopathy. Tell your provider right away if you experience changes in vision.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Suicidal Behavior and Ideation: </strong>You should pay attention to any mental health changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you.<br><br><span class="text-span-14"><strong>•</strong></span><strong>Never Share a Pen:</strong> Pen-sharing poses a risk of infection.<br>‍<br><br><span class="text-span-14"><strong>What are the most common side effects of Zepbound?</strong></span><br><br><span class="text-span-14"><strong>•</strong></span><strong>Nausea<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Diarrhea<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Vomiting<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Constipation<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Indigestion<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Injection site reactions<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Fatigue<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Allergic reactions<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Belching<br></strong><span class="text-span-14"><strong>•</strong></span><strong>Hair loss</strong><span class="text-span-14"><br><strong>•</strong></span><strong>Gastroesophageal reflux disease</strong><br><br><span class="text-span-14"><strong><br>You are encouraged to report negative side effects of prescription products to the FDA:</strong></span><br><span class="text-span-14"><strong>•</strong></span><strong>Visit www.fda.gov/medwatch or call 1-800-FDA-1088.<br><br></strong><span class="text-span-14"><strong>Before using Compound Tirzepatide<br><br>•</strong></span>Your healthcare provider should show you how to use Compound Tirzepatide before you use it for the first time.<strong><br>‍</strong><span class="text-span-14"><strong>•</strong></span>Tell your healthcare provider if you are taking medicines to treat diabetes including insulin or sulfonylureas which could increase your risk of low blood sugar. Talk to your healthcare provider about low blood sugar levels and how to manage them.<strong><br>‍</strong><span class="text-span-14"><strong>•</strong></span>If you take birth control pills by mouth, talk to your healthcare provider before you use Compound Tirzepatide. Birth control pills may not work as well while using Compound Tirzepatide. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Compound Tirzepatide and for 4 weeks after each increase in your dose of Compound Tirzepatide.<br><br><br><span class="text-span-14"><strong>Review these questions with your healthcare provider:<br>‍<br>•</strong></span>Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?<strong><br>‍</strong><span class="text-span-14"><strong>•</strong></span>Do you take diabetes medicines, such as insulin or sulfonylureas ?<strong><br>‍</strong><span class="text-span-14"><strong>•</strong></span>Do you have a history of diabetic retinopathy?<br>‍<span class="text-span-14"><strong>•</strong></span>Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?<br><span class="text-span-14"><strong>•</strong></span>Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Compound Tirzepatide may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Compound Tirzepatide. It is not known if Compound Tirzepatide passes into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Compound Tirzepatide.<br><br><br><span class="text-span-14"><strong>How to take<br>‍<br>•</strong></span>Read the Instructions for Use that come with Compound Tirzepatide.<br>‍<span class="text-span-14"><strong>•</strong></span>Use Compound Tirzepatide exactly as your healthcare provider says.<strong><br>‍</strong><span class="text-span-14"><strong>•</strong></span>Compound Tirzepatide is injected under the skin(subcutaneously) of your stomach(abdomen), thigh, or upper arm.<br>‍<span class="text-span-14"><strong>•</strong></span>Use CompoundTirzepatide 1 time each week, at any time of the day.<br><span class="text-span-14"><strong>•</strong></span>Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection.<strong><br>‍</strong><span class="text-span-14"><strong>•</strong></span>If you take too much Compound Tirzepatide, call your healthcare provider, seek medical advice promptly, or contact a Poison Center expert right away at 1-800-222-1222.<br><br><br><span class="text-span-14"><strong>Learn More<br>‍</strong></span><br>Compound Tirzepatide is a prescription medicine. For more information on tirzepatide-containing products, please call 1-828-221-2549 to learn more or receive information regarding how to contact your pharmacy.This summary provides basic information about Compound Tirzepatide but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Compound Tirzepatide and how to take it. Your healthcare provider is the best person to help you decide if Compound Tirzepatide is right for you.<br><br></p>
    </div>
  </section>
  <section>
    <div class="div-block-446">
      <div class="div-block-447">
        <div class="div-block-982">
          <a href="old-home.html" class="w-inline-block"><img src="images/yara-placeholder-W.svg" loading="lazy" alt="" class="image-6"></a>
          <div class="text-block-54">© 2023</div>
        </div>
        <div class="div-block-980">
          <div class="text-block-164">About Us</div>
          <a href="returns.html" class="link-10">Yara is a subsidiary of WG Holdings.<br>An American company based in Puerto Rico.<br><br>875 Carr 693, Suite 205<br>Dorado PR 00646<br><br>1-828-221-2549<br> </a>
        </div>
        <div class="div-block-980">
          <div class="text-block-164">Contact</div>
          <a href="tel:+18282212549" class="link-10">Call Us</a>
          <a href="mailto:help@joinyara.com?subject=I%20need%20help!" class="link-10">Email Us</a>
        </div>
        <div class="div-block-980">
          <div class="text-block-164">Legal</div>
          <a href="hippa-notice.html" class="link-10">HIPAA Notice</a>
          <a href="privacy-policy-new.html" class="link-10">Privacy Policy</a>
          <a href="returns.html" class="link-10">Returns &amp; Refund Policy</a>
          <a href="terms.html" class="link-10">Terms Of Use</a>
          <a href="ccpa-opt-out.html" class="link-10">CCPA Opt-Out</a>
          <a href="tele-health-consent.html" class="link-10">Tele Health Consent</a>
          <a href="30daychallengetc.html" class="link-10">30 Day Challenge <br>Terms &amp; Conditions</a>
          <a href="safety.html" aria-current="page" class="link-10 w--current">Safety</a>
        </div>
      </div>
    </div>
  </section>
  <script src="https://d3e54v103j8qbb.cloudfront.net/js/jquery-3.5.1.min.dc5e7f18c8.js?site=657b2233d6a286f5c9f3844c" type="text/javascript" integrity="sha256-9/aliU8dGd2tb6OSsuzixeV4y/faTqgFtohetphbbj0=" crossorigin="anonymous"></script>
  <script src="js/webflow.js" type="text/javascript"></script>
</body>
</html>